A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand

Table 2 ICER of related HSCT compared to BT-ICT, classified by patient age

Age (year)	Incremental cost	Incremental QALY	ICERs of related HSCT compared to BT-ICT
	million THB	QALY gained	THB per QALY gained*
1	0.81	10.00	80,700
5	0.78	8.96	86,800
10	0.72	7.02	103,000
15	0.61	3.32	183,000
17	0.55	2.14	257,000
18	0.55	1.78	308,000
19	0.48	0.84	574,000
20	0.40	-0.20	Dominated^§
25	0.30	-2.05	Dominated^§
28	0.31	-2.17	Dominated^§

ICER: incremental cost-effectiveness ratio; HSCT: hematopoietic stem cell transplantation; BT-ICT: blood transfusion combined with subcutaneous iron chelating therapy; THB: Thai baht (in 2008 value); and QALY: quality adjusted life year.
*ICERs are rounded up to nearest 1,000 THB.
^§Negative ICER due to higher effectiveness and lower costs of BT-ICT compared with HSCT.

ISSN: 1472-6963